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Abstract
Background: The impacts of weight loss on prognosis in nasopharyngeal carcinoma (NPC) remain unclear. The
present study was therefore undertaken to investigate the association between critical weight loss and long-term
survival in NPC patients.
Methods: The eligible 2399 NPC patients were reviewed. Weight change was categorized into critical weight loss
(CWL) and non-critical weight loss (Non-CWL). The associations of CWL with long-term survival were analyzed by
Cox regression in the entire patient and two subsets. Propensity score matching was performed to reduce the
effects of confounding factors.
Results: CWL was defined as body weight loss of ≥4.6 %. Compared with patients without CWL, patients with
CWL had significantly lower 5-year OS (72.4 vs. 79.3 %, P < 0.001), FFS (71.1 vs. 78.4 %, P <0.001), and LR-FFS (78.1
vs. 84.8 %, P <0.001), respectively. After adjustment for potential confounders, CWL remained an independence
prognostic factor for OS (HR = 1.352; 95 % CI 1.160–1.576; P < 0.001), FFS (HR = 3.275; 95 % CI 1.101–9.740; P = 0.033),
and LR-FFS (HR = 6.620; 95 % CI 2.990–14.658; P < 0.001), respectively. Furthermore, subgroup analysis in the cohort
of patients received concurrent chemoradiotherapy or radiotherapy alone confirmed the results in the entire
patient even after the propensity-score matching. In IMRT cohort, CWL was also significantly associated with a
lower OS (P = 0.04) and FFS (P = 0.04).
Conclusions: CWL has a significant and independent impact on long-term survival in nasopharyngeal
carcinoma patients.
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Background
Body weight loss (WL) during radiotherapy is a fre-
quently observed problem among patients with head
and neck cancer (HNC) [1–4], but there have been con-
troversies over the impact of weight loss during radio-
therapy on survival. In the study of Pai et al. [5],
comparing with patients with less WL, patients with
greater WL during radiotherapy have significantly worse
survival in patients with higher pre-radiotherapy body
mass index (BMI). Two 2013 studies found weight loss
is an independent prognostic factor for disease-free sur-
vival, but not for overall survival [6, 7]. Nasopharyngeal
carcinoma (NPC) is a distinct form of HNC due to
unique clinical, etiological and biological characteristics
[8–10]. Shen et al. [11] reported high weight loss is inde-
pendently associated with poor survival in NPC patients
with lower BMI. To date, the impact of weight loss on
long-term survival in NPC patients remain unclear,
given the diversity of chemotherapy regimen and radio-
therapy technique.
In the present study, we used data obtained from a
large database of NPC patients in our institute to in-
vestigate the association between weight loss and
long-term survival in the entire patient and its two
subsets. Propensity score matching was performed to
reduce the effects of confounding factors.
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From a cohort of newly diagnosed nasopharyngeal car-
cinoma patients between January 2001 and January
2005, this study was approved by the ethics committee
of Sun Yat-sen University Cancer Center. This was a
retrospective analysis of routine data and therefore we
were granted a waiver of individual informed consent
from the ethics committee of Sun Yat-sen University.
The data were collected by trained interviewers and
analyzed anonymously. Patients who met the following
criteria were selected: (i) Histologically confirmed non-
keratinizing or undifferentiated NPC (World Health
Organization type II or III); (ii) patients newly diag-
nosed without evidence of systemic metastasis; (iii) KPS
(Karnofsky performance scale) score ≥80; (iv) Comple-
tion of the scheduled total radiotherapy dose. The
exclusion criteria included: lack of complete weight
measurement at baseline and/or at the end of radio-
therapy. The final study cohort was composed of 2399
patients. All patients were evaluated by the following
examinations before treatment: complete patient his-
tory, physical examination, CT or MRI of the neck and
nasopharynx, chest radiography, abdominal sonog-
raphy, and acquisition of whole body bone scans by
single photon emission computed tomography (ECT).
Data collection
Medical records were reviewed to extract data on patient
and tumor characteristics, including age, gender, the
sixth edition of Union for International Cancer Control
/American Joint Committee on Cancer (UICC/AJCC)
stage [12], radiotherapy techniques and dose, treatment
group (radiotherapy or combined chemo-radiotherapy),
BMI [defined as pre-radiotherapy weight (kg) divided by
the square of height (meter)], smoking status at diagno-
sis, categorized into two groups: (i) never-smokers
referred to patients who never smoke; (ii) ex-smokers re-
ferred to former smokers who had stopped smoking and
smokers who smoking until the day of hospitalization.
Pre-radiotherapy body weight was measured within
7 days before radiotherapy (RT), and post-radiation
body weight was measured within 7 days after com-
pletion of RT. Weight loss was based on the equation
(Pre-radiotherapy weight –Post-radiotherapy weight)/
Pre-radiotherapy weight × 100 %.
Treatment
Radiotherapy techniques included two-dimensional
conventional radiotherapy, which included X-ray
simulation (n = 1897) and CT simulation (n = 315) for
radiotherapy treatment planning, three-dimensional
conformal radiotherapy (3D-CRT, n = 49), intensity-
modulated radiotherapy (IMRT, n = 138). These details
have been previously described by Shen et al.[11].
Briefly, Conventional radiation therapy was performed
by 2 Gy per fraction with five daily fractions per week
up to a total dose of 68–78 Gy. For 3D-CRT, the total
prescribed dose was 66–72 Gy to the gross tumor vol-
ume of nasopharynx (GTVnx), 60 to 70 Gy to the
region involved by the metastatic lymph nodes
(GTVnd). For IMRT, the prescription dose was 68 Gy
to GTVnx, 60 to 64 Gy to GTVnd. Combined modal-
ity therapy for most locoregionally advanced NPC
included induction chemotherapy followed by concur-
rent chemoradiotherapy (n = 184), concurrent chemo-
radiotherapy (n = 306), induction chemotherapy (n =
494), induction chemotherapy or concurrent chemora-
diotherapy plus adjuvant chemotherapy (n = 50), and
miss data (n = 299). The induction or adjuvant chemo-
therapy regimen was mainly cisplatin plus fluorouracil
(5-Fu), with cisplatin (70 to 100 mg/m2) given on Day 1
and 5-fluorouracil (500 to 750 mg/m2) on Days 1–5, re-
peated every 3–4 weeks, for 2 to 3 cycles. The concur-
rent chemotherapy regimen was mainly cisplatin alone,
with cisplatin (30–40 mg/m2 on Day 1) given intraven-
ously weekly for 5–7 weeks or cisplatin (80–100 mg/
m2) given intravenously 3-weekly for three cycles.
Follow-up and end points
The primary endpoint was overall survival rates (OS),
the secondary endpoints were failure-free survival rates
(FFS), locoregional failure-free survival rates (LR-FFS),
and distant failure-free survival rates (D-FFS). OS was
defined as the length of time from the date of beginning
therapy to the date of death from any cause. FFS was de-
fined as the time between the date of beginning therapy
and the date of treatment failure or death from any
cause, whichever was first. LR-FFS was defined as the
time to first recurrence at the nasopharyngeal region
and/or in the cervical region after radiotherapy, not
including salvage procedures. D-FFS was defined as
the time from the date of beginning therapy to the
first distant failure. The last follow-up visit occurred
in August 2011.
Statistical analysis
Categorical variables were compared with χ2 tests (or
Fisher’s exact test, if indicated) and continuous variables
with Student’s t test. Receiver operating characteristic
curve (ROC) analysis was used to select the cutoff point
of weight loss. Survival analysis was carried out using
the Kaplan–Meier method and compared with the log-
rank test. Multivariate analyses with the Cox propor-
tional hazards model were used to test for independent
significance by backward elimination of insignificant ex-
planatory variables of the different parameters. The Cox
proportional hazards model was also used to calculate
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the hazard ratio (HR). The interaction between weight
loss and BMI was assessed using Cox regression. The
statistical analyses were performed using SPSS version
19.0 (SPSS, Inc., an IBM Company, Chicago, IL, USA).
A two-sided P-value <0.05 was taken as statistically
significant. Given the differences in the baseline char-
acteristics between critical weight loss and non-critical
weight loss groups, propensity-score matching in R
Statistical Software (version 3.1.3; R Foundation for
Statistical Computing, Vienna, Austria) was performed
using the MatchIt package with nearest-neighbor 1-to-
1 matching [13].
Results
Demographic, patterns of treatment failure, and survival
A total of 2399 nasopharyngeal carcinoma patients were
included in this study, with a median age of 46 years
(range, 13–78 years). The ratio of male to female was
3.19:1, with 1826 males and 573 females. The sixth
edition of the UICC/AJCC clinical stage distribution
was: stage I, 126 (5.3 %); stage IIa, 23 (1.0 %); stage
IIb, 816 (34.0 %); stage III, 971 (40.5 %), and stage
IVa 377 (15.7 %); and stage IVb 86 (3.6 %). Overall,
1066 (44.4 %) patients were treated with radiother-
apy (RT) alone and 1333 (55.6 %) received combined
chemo-radiotherapy (CRT). The median follow-up
for the whole group was 85.3 months (range: 1.6–
124.7 months), for alive patients was 93.6 months
(range:74.2–124.7 months). 546 (22.8 %) patients de-
veloped locoregional relapse, 158 (6.6 %) developed
distant metastases, and 729 (30.4 %) died. The 3-
and 5-year survival rates were as follows: OS, 84.2
and 75.4 %; FFS, 82.9 and 74.3 %; LR-FFS, 87.7 and
81.1 %; and D-FFS, 95.7 and 94.2 %.
Determination of cutoff points for weight loss and the
distribution of patients characteristics in the entire
patient cohort
Because OS was the primary endpoint in this study, the
cutoff point for OS was selected as the optimal cutoff
value using ROCanalysis. The result indicated the cutoff
value of weight loss was 4.6 % (the sensitivity was 62.7 %
and the specificity was 46.9 %) with an area of 0.546
(95 % CI, 0.521–0.572; P <0.001). Critical weight loss
(CWL) was defined as body weight loss of ≥4.6 %. CWL
was observed in 56.0 % (1343/2399) of patients. Mean
weight loss was 9.1 (±3.6) %. In patients without critical
weight loss, 656 patients (62.1 %) had <4.6 % weight loss,
152 patients (14.4 %) had no weight loss, and 248 pa-
tients (23.5 %) had weight gain. As shown in Table 1,
there were no differences in the distribution of gender,
smoking status or radiotherapy dose for the entire pa-
tient cohort when categorized by cut-off points. How-
ever, significant differences were observed in terms of
age, clinical stage, T-stage, N-stage, treatment group,
and BMI. Older patients and higher BMI were more fre-
quent in patients with CWL. In addition, patients with-
out critical weight loss exhibited more patients with
advanced T-stage, N-stage, or clinical stage. Accord-
ingly, the proportion of patients received combined
chemoradiotherapy was higher in the non-critical
weight loss group.
Impact of critical weight loss on survival in the entire
patient
Compared with patients without CWL, patients with
CWL had significantly lower 5-year OS (72.4 vs. 79.3 %,
P < 0.001; Fig. 1a), FFS (71.1 vs. 78.4 %, P <0.001; Fig. 1b),
and LR-FFS (78.1 vs. 84.8 %, P <0.001; Fig. 1c), respect-
ively. No significant benefit was observed for D-FFS
(94.3 vs. 94.1 %, P =0.702; Fig. 1d) between the two
groups. The unadjusted Cox regression analysis (Table 2)
showed that critical weight loss was significantly associated
Table 1 Baseline characteristics of nasopharyngeal carcinoma
patients with and without critical weight loss
Characteristics Non-critical weight






45 (13–78) 46 (13–78) 0.004
Gender (%)
Male 817 (77.4) 1009 (75.1) 0.202
Female 239 (22.6) 334 (24.9)
Clinical stage (%)
I-II 476 (45.1) 489 (36.4) <0.001
III-IV 580 (54.9) 854 (63.6)
T-stage (%)
T1-2 648 (61.4) 745 (55.5) 0.004
T3-4 408 (38.6) 598 (44.5)
N-stage (%)
N0-1 744 (70.5) 841 (62.6) <0.001
N2-3 312 (29.5) 502 (37.4)
Treatment
group (%)
RT 547 (51.8) 519 (38.6) <0.001
CRT 509 (48.2) 824 (61.4)
Smoking
status (%)
never-smokers 552 (52.3) 697 (51.9) 0.856
ex-smokers 504 (47.7) 646 (48.1)
RT dose (Gy),
media (range)
70 (60–87) 70 (60–86) 0.127
BMI (kg/m2),
media (range)
22.04 (14.04–35.36) 22.77 (13.61–39.06) <0.001
Notes: critical weight loss: weight loss ≥ 4.6 %; RT Radiotherapy alone, CRT
Combined chemo-radiotherapy, BMI Pre-RT weight (kg) divided by the square
of height (meter)
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with a worse OS (HR = 1.411; 95 % CI 1.214–1.639; P <
0.001), FFS (HR = 1.383; 95 % CI 1.193–1.603; P < 0.001),
and LR-FFS (HR = 1.487; 95 % CI 1.248–1.771; P < 0.001).
After adjustment for age (continuous variable), gender (fe-
male vs. male), T stage (T1-2 vs. T3-4), N stage (N0-1 vs.
N2-3), treatment group (RT vs. CRT), BMI (continuous
variable), smoking status (never smokers vs. ex-smokers),
radiotherapy dose (continuous variable), and (weight loss) ×
BMI, critical weight loss remained an independent prog-
nostic factor for OS (HR = 1.352; 95 % CI 1.160–1.576; P
Fig. 1 Comparison of survival between patients with and without CWL
Table 2 Cox regression analyses of the association between critical weight loss and survival in the entire patient cohort and its two subsets
OS FFS LR-FFS D-FFS
HR (95 % CI) P HR (95 % CI) P HR (95 % CI) P HR (95 % CI) P
Patient cohort (n = 2399)
Unadjusted model 1.411 (1.214–1.639) <0.001 1.383 (1.193–1.603) <0.001 1.487 (1.248–1.771) <0.001 0.941 (0.688–1.287) 0.702
Adjusted model 1.352 (1.160–1.576) <0.001 3.275 (1.101–9.740) 0.033 6.620 (2.990–14.658) <0.001 1.432 (0.149–13.736) 0.755
Subset I (n = 1374)
Matched/Unadjusted model 1.554 (1.259–1.917) <0.001 1.539 1.251–1.895) <0.001 1.577 (1.241–2.004) <0.001 1.276 (0.763–2.134) 0.352
Matched/Adjusted model 1.515 (1.227–1.871) <0.001 1.504 (1.221–1.852) <0.001 9.395 (2.965–29.765) <0.001 0.846 (0.02–36.683) 0.931
Subset II (n = 110)
Matched/Unadjusted model 4.857 (1.049–22.483) 0.043 4.857 (1.049–22.483) 0.043 5.143 (0.601–44.027) 0.135 2.037 (0.185–22.470) 0.560
Matched/Adjusted model 4.998 (1.080–23.141) 0.040 4.986 (1.077–23.086) 0.040 5.356 (0.623–46.011) 0.126 1.656 (0.144–19.117) 0.680
Notes: Patient cohort: the entire patients; Subset I: the patient cohort received radiotherapy alone or concurrent chemoradiotherapy after matching. Subset II: The patient
cohort received IMRT after matching. Critical weight loss: weight loss ≥4.6 %. Adjusted for age (continuous variable), gender (female vs. male), UICC T stage (T1-2 vs. T3-4),
UICC N stage (N0-1 vs. N2-3), treatment group (RT vs. CRT), BMI (continuous variable), smoking status (Never smokers vs. ex-smokers), radiotherapy dose (continuous variable)
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< 0.001), FFS (HR = 3.275; 95 % CI 1.101–9.740; P =
0.033), and LR-FFS (HR = 6.620; 95 % CI 2.990–
14.658; P < 0.001). There were no interactions be-
tween weight loss and BMI for OS (P = 0.119), FFS
(P = 0.099), D-FFS (P = 0.993). For LR-FSS, the
(weight loss) × BMI interaction term was significant
(P < 0.001).
Impact of critical weight loss on survival in the patients
received concurrent chemoradiotherapy or radiotherapy
alone
The modes of chemotherapy in our study varied differ-
ently, which might have a confounding effect. Patients
received induction chemotherapy alone and adjuvant
chemotherapy was excluded. We developed a new
cohort to analyze the impact of CWL on survival, in
which patients received radiotherapy alone (n = 1066),
concurrent chemoradiotherapy alone (n = 306) or
induction chemotherapy plus concurrent chemoradio-
therapy (n = 184). The characteristics of the patient co-
hort were summarized in Table 3. The propensity-score
matching was performed to reduce the differences in the
baseline characteristics, matching variables included age,
clinical stage, T-stage, N-stage, treatment group, radio-
therapy dose, BMI. After matching, baseline characteris-
tics were similar in the two groups (Table 3). Figure 2
shows the histograms before and after matching. The
histograms before matching on the left differ to a
great degree. The histograms after matching on the
right are very similar.
The unadjusted Cox regression analysis after pro-
pensity score matching showed that CWL (table 2)
was significantly associated with a worse OS (HR =
1.554; 95 % CI 1.259–1.917; P < 0.001), FFS (HR =
1.539; 95 % CI 1.251–1.895; P < 0.001), and LR-FFS
(HR = 1.577; 95 % CI 1.241–2.004; P < 0.001). After
adjustment for age (continuous variable), gender
(female vs. male), T stage (T1-2 vs. T3-4), N stage
(N0-1 vs. N2-3), treatment group (RT vs. CRT), BMI
(continuous variable), smoking status (never smokers
vs. ex-smokers), radiotherapy dose (continuous vari-
able), CWL remained an independent prognostic fac-
tor for OS (HR = 1.515; 95 % CI 1.227–1.871; P <
0.001), FFS (HR = 1.504; 95 % CI 1.221–1.852; P <
0.001), and LR-FFS (HR = 9.395; 95 % CI 2.965–
29.765; P < 0.001).
Table 3 Characteristics stratified by critical weight loss before and after propensity-score matching in patients received radiotherapy
alone or concurrent chemoradiotherapy
Before Matching After Matching
Characteristics Non-CWL (N = 687) CWL (N = 869) P Non-CWL (N = 687) CWL (N = 687) P
Age (y) media (range) 45 (13–78) 47 (14–77) 0.005 45 (13–78) 46 (15–77) 0.050
Sex (%)
Male 522 (76.0) 657 (75.6) 0.863 522 (76.0) 518 (75.4) 0.801
Female 165 (24.0) 212 (24.4) 165 (24.0) 169 (24.6)
Clinical stage (%)
I-II 388 (56.5) 381 (43.8) <0.001 388 (56.5) 352 (51.2) 0.051
III–IV 299 (43.5) 488 (56.2) 299 (43.5) 335 (48.8)
T-stage (%)
T1-2 481 (70.0) 529 (60.9) <0.001 481 (70.0) 458 (66.7) 0.182
T3-4 206 (30.0) 340 (39.1) 206 (30.0) 229 (33.3)
N-stage (%)
N0-1 536 (78.0) 592 (68.1) <0.001 536 (78.0) 521 (75.8) 0.337
N2-3 151 (22.0) 277 (31.9) 151 (22.0) 166 (24.2)
Treatment group (%)
RT 547 (79.6) 519 (59.7) <0.001 547 (79.6) 509 (74.1) 0.015
CRT 140 (20.4) 350 (40.3) 140 (20.4) 178 (25.9)
Smoking status (%)
never-smokers 375 (54.6) 450 (51.8) 0.272 375 (54.6) 365 (53.1) 0.588
ex-smokers 312 (45.4) 419 (48.2) 312 (45.4) 322 (46.9)
RT dose (Gy), media (range) 70 (60–87) 70 (60–86) 0.081 70 (60–87) 70 (60–86) 0.599
BMI (kg/m2) media (range) 22.05 (14.04–34.89) 22.83 (15.35–39.06) <0.001 22.05 (14.04–34.89) 22.41 (15.35–32.99) 0.058
Notes: RT Radiotherapy alone, CRT Combined chemo-radiotherapy, BMI Pre-RT weight (kg) divided by the square of height (meter)
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Impact of critical weight loss on survival in IMRT cohort
There were 138 patients received IMRT in the study.
Further analysis was performed in IMRT cohort. Table 4
showed the characteristics of the patients before and
after propensity score matching. Total fifty-five pairs
were confirmed and baseline characteristics were similar
in the two groups after matching. The multivariate ana-
lysis was performed in the IMRT cohort with the covari-
ates, including age (continuous variable), gender (female
vs. male), T stage (T1-2 vs. T3-4), N stage (N0-1 vs. N2-
3), treatment group (RT vs. CRT), BMI (continuous vari-
able), smoking status (never smokers vs. ex-smokers),
radiotherapy dose (continuous variable), Patients with
CWL had an HR of death of 4.998 (95 % CI, 1.080-
23.141; P = 0.040), HR of disease failure of 4.986 (95 %
CI, 1.077–23.086; P = 0.040) compared with patients
without CWL. But CWL wasn’t significantly associate
with LR-FFS (P = 0.126) and D-FFS (P = 0.680).
Revalidation of the impact of weight loss on survival by
another threshold of critical weight loss
To further clarify the impact of weight loss on survival, a
recommended threshold of CWL (≥5 %) by the American
Society for Parenteral and Enteral Nutrition was used, and
the entire patient was divided into three categories: pa-
tients with ≥5 % weight loss (n = 1277); patients with <5 %
weight loss (n = 722); patients with weight gain and with-
out weight loss (n = 400). As showed in Additional file 1:
Figure S1, No significant benefit was observed for 5-year
OS (79.5 vs. 77.5 %, P =0.401) between patients with <5 %
weight loss and patients with weight gain and without
weight loss (n = 400). However, compared with the above
two categories, patients with ≥5 % weight loss had signifi-
cantly lower 5-year OS (72.4 %, P < 0.05). These results
confirmed our conclusions.
Discussion
Weight loss is common among HN cancer patients, es-
pecially for those with advanced tumor stage, or a higher
body mass index before treatment, or the use of concur-
rent chemotherapy [3, 14]. Several different definitions
were used to define critical / high weight loss or severe
malnutrition [2, 6, 11, 15, 16]. We defined critical weight
loss as body weight loss of ≥4.6 %, based on the result of
ROC analysis for OS in the entire patient, because OS
was the primary endpoint in this study. The ratio of crit-
ical weight loss in HNC patients was reported to vary
from 19 % to 60 % [3, 11, 17, 18], in the present study,
56.0 % (1343/2399) patients developed CWL. Although
over half of patients presented with CWL during radio-
therapy, there was limited information regarding the
association between CWL and long-term survival. The
aim of the present study is to elucidate the impact of
CWL on survival in NPC patients and provide new clues
for clinical intervention to improve their survival.
Fig. 2 Histograms of propensity scores before and after matching in patients received radiotherapy alone or concurrent chemoradiotherapy CWL:
critical weight loss (weight loss ≥4.6 %)
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In our study, after adjustment for all the potential con-
founding factors, patients with CWL had an HR of death
of 1.352 (95%CI 1.160–1.576; P < 0.001), HR of disease
failure of 3.275 (95 % CI, 95 %CI 1.101–9.740; P =
0.033), and HR of locoregional recurrence of 6.620
(95%CI 2.990–14.658; P < 0.001) compared with patients
without critical weight loss. The WL × BMI interaction
term was significant (P < 0.001) only for LR-FSS, indicat-
ing that the prognostic impact of weight loss differed
significantly on the basis of BMI. Furthermore, given the
diversity of chemotherapy modality and radiotherapy
technique, we developed two additional subsets to con-
firm the results. In addition, regression analysis cannot
reliably adjust for differences in covariates when there
are substantial differences in the distribution of these
covariates between two groups. When regression ap-
proaches cannot remove all or nearly all the bias, alter-
native strategies such as propensity score matching can
be used [19]. In the cohort of patients received concur-
rent chemoradiotherapy and radiotherapy, excluding the
interference of induction chemotherapy alone and adju-
vant chemotherapy, CWL remain an independent prog-
nostic factor for OS, FFS, LR-FFS even after propensity
score matching. In addition, IMRT has been shown to
increase the locoregional control probability while de-
creasing the complication rate [20, 21], in the IMRT co-
hort of our study, Patients with CWL had an HR of
death of 4.998 (95 % CI, 1.080–23.141; P = 0.040), HR of
disease failure of 4.986 (95 % CI, 1.077–23.086; P =
0.040) compared with patients without CWL. But CWL
wasn’t significantly associate with LR-FFS (P = 0.126) in
IMRT cohort. It is likely that the sample size (n = 110)
was not large enough to ensure adequate power.
Taken together, our results mirror and extend the find-
ings of previous studies and provide additional evidence
that critical weight loss (≥4.6 %) was an independent
prognostic factor for OS, FFS, and LR-FFS, irrespective
of chemotherapy modality, radiotherapy technique, and
BMI. The underlying reason may mainly involve malnu-
trition. Previous studies showed patients presenting with
malnutrition experience more unplanned treatment de-
lays or interruptions and poor overall survival in HNC
patients [16, 22, 23]. Conversely, well-nourished patients
can tolerate treatment better with fewer complications,
recover faster after treatment and maximize quality of
life [24–27]. In addition, during curative treatment (es-
pecially concurrent chemoradiotherapy) in NPC pa-
tients, the majority of patients present treatment-related
Table 4 Characteristics stratified by critical weight loss before and after propensity-score matching in patients received IMRT
Before Matching After Matching
Characteristics Non-CWL (N = 55) CWL (N = 83) P Non-CWL (N = 55) CWL (N = 55) P
Age (y) media (range) 41 (18–60) 42 (13–73) 0.538 41 (18–60) 40 (15–67) 0.832
Sex (%)
Male 39 (70.9) 63 (75.9) 0.513 39 (70.9) 41 (74.5) 0.669
Female 16 (29.1) 20 (24.1) 16 (29.1) 14 (25.5)
Clinical stage (%)
I-II 24 (43.6) 20 (24.1) 0.016 24 (43.6) 19 (34.5) 0.329
III-IV 31 (56.4) 63 (75.9) 31 (56.4) 36 (65.5)
T-stage (%)
T1-2 30 (54.5) 36 (43.4) 0.198 30 (54.5) 24 (43.6) 0.252
T3-4 25 (45.5) 47 (56.6) 25 (45.5) 31 (56.4)
N-stage (%)
N0-1 44 (80.0) 40 (48.2) <0.001 44 (80.0) 38 (69.1) 0.189
N2-3 11 (20.0) 43 (51.8) 11 (20.0) 17 (30.9)
Treatment group (%)
RT 34 (61.8) 24 (28.9) <0.001 34 (61.8) 23 (41.8) 0.036
CRT 21 (38.2) 59 (71.1) 21 (38.2) 32 (58.2)
Smoking status (%)
Never-smokers 33 (60.0) 48 (57.8) 0.800 33 (60.0) 31 (56.4) 0.699
Ex-smokers 22 (40.0) 35 (42.2) 22 (40.0) 24 (43.6)
RTdose (Gy), media (range) 68 (66–81) 68 (66–68) 0.289 68 (66–81) 68 (66–88) 0.254
BMI (kg/m2), media (range) 23.34 (14.86–30.08) 23.23 (15.35–30.82) 0.565 23.34 (14.86–30.08) 23.23 (15.35–30.82) 0.268
Abbreviations: RT Radiotherapy alone, CRT Combined chemo-radiotherapy, BMI Pre-RT weight (kg) divided by the square of height (meter)
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toxicities, of which dysphagia caused by acute mucositis
is one of the most prominent [28]. These acute toxicities
bring to discomfort and difficulties with eating. Then
insufficient food intake in the malnourished patients im-
paired the immune system [29], which further compro-
mised the effect of radiotherapy on localregional control
[30–32]. Moreover, it has been confirmed that that a se-
vere deficiency of peripheral blood iNKT cells in patients
with head and neck cancer was significantly related to
poor clinical outcome [33]. Langius et al. [6] found that
patients with CWL had significantly lower numbers of T
cells and more often a low iNKT cell level compared
with patients without CWL. In brief, weight loss is one
of the main symptoms of malnutrition, which further
cause immune suppression.
In this study a significant and independent impact of
CWL on long-term survival of nasopharyngeal carcin-
oma patients was established. Thus clinical intervention
to prevent therapy-associated weight loss was war-
ranted. Clinical guidelines recommend enteral nutrition
should be started if undernutrition already exists or if
food intake is markedly reduced for more than 7–10
days [34], but both the enteral feeding methods and
what the supplemental formula should contain are still
debated [35, 36]. Further studies will be needed to ad-
dress the research gaps in NPC.
Our study has several strengths. Firstly, we performed
multivariate analyses adjusted for age, gender, T stage, N
stage, treatment group, BMI, smoking status, radiother-
apy dose, while most of previous studies analyzed the
effect of CWL on the prognostic without adequate ad-
justment for relevant prognostic factors, thus significant
differences were covered by other confounding variables.
Secondly, two subsets were developed to confirm the
significant differences. Lastly, we further carried out pro-
pensity score matching in two subsets to adjust for
differences in baseline data. Based on these observations,
we feel confident in our results.
Still, the limitations of our study are related to its
retrospective nature and the data were obtained exclu-
sively at one center. Next, Comorbidities like cardiovas-
cular diseases, diabetes significantly affect prognosis of
NPC patients [37], and further exacerbate malnutrition.
However comorbidities appear to be more common in
elderly patients, the percentage of elderly patients (≥65)
in our study are relatively small (7.9 %), thus the poten-
tial confounding effect of comorbidities is not the main
aspect. Thirdly, the sample size (n = 110) in IMRT cohort
is not large enough to ensure adequate power.
Conclusions
In summary, our data suggest that critical weight loss
has a significant and independent impact on long-term
survival in nasopharyngeal carcinoma patients. There is
a clear distinction between patients with and without
CWL. This emphasizes the importance of identification
and optimal treatment of weight loss during NPC treat-
ment in future.
Additional file
Additional file 1: Figure S1. Comparison of overall survival among
patients with ≥5 % weight loss, patients with <5 % weight loss, and
patients with weight gain and without weight loss. (TIF 34 kb)
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